Literature DB >> 16945414

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.

Jana Rulcová1, Václava Zmeková, Zuzana Zemanová, Hana Klamová, Jana Moravcová.   

Abstract

We compared the effect of control genes (CG): total Abelson (total-ABL), beta-2-microglobulin (B2M) and beta-glucuronidase (GUS), recommended in the Europe Against Cancer (EAC) program, on real-time BCR-ABL monitoring in patients with chronic myeloid leukemia (CML). We focused on the stability of CG expressions during therapy and the effect of the CGs on BCR-ABL ability to characterize the disease status and disease prognosis, issues that have not been addressed yet. The results showed B2M as a very convenient CG for BCR-ABL monitoring. On the contrary, the widely used total-ABL was not confirmed as appropriate for normalization of gene expression in CML.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16945414     DOI： 10.1016/j.leukres.2006.07.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  8 in total

1.  Evaluation of the Abelson gene as a control gene for real-time quantitative PCR in multiple myeloma.

Authors:  Yao Zhang; Guo-Rui Ruan
Journal:  Clin Exp Med       Date:  2013-08-30       Impact factor: 3.984

2.  Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.

Authors:  Tong Zhang; Sylvie Grenier; Bevoline Nwachukwu; Cuihong Wei; Jeffrey H Lipton; Suzanne Kamel-Reid
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

3.  High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.

Authors:  Yuko Doi; Daisuke Sasaki; Chiharu Terada; Sayaka Mori; Kazuto Tsuruda; Emi Matsuo; Yasushi Miyazaki; Kazuhiro Nagai; Hiroo Hasegawa; Katsunori Yanagihara; Yasuaki Yamada; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2009-05-23       Impact factor: 2.490

4.  Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.

Authors:  Chikashi Yoshida; Linda Fletcher; Kazuteru Ohashi; Hisashi Wakita; Takashi Kumagai; Masayuki Shiseki; Kousei Matsuei; Koiti Inokuchi; Yoshihiro Hatta; Yukari Shirasugi; Toshikazu Yamaguchi; Junichi Sakamoto; Susan Branford; Hisashi Sakamaki
Journal:  Int J Clin Oncol       Date:  2011-10-12       Impact factor: 3.402

5.  Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.

Authors:  Fei Bao; Reinhold Munker; Clarissa Lowery; Sherry Martin; Runhua Shi; Diana M Veillon; James D Cotelingam; Mary Lowery Nordberg
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  Expression patterns of microRNAs associated with CML phases and their disease related targets.

Authors:  Kateřina Machová Poláková; Tereza Lopotová; Hana Klamová; Pavel Burda; Marek Trněný; Tomáš Stopka; Jana Moravcová
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

7.  Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.

Authors:  Ingmar Glauche; Matthias Kuhn; Christoph Baldow; Philipp Schulze; Tino Rothe; Hendrik Liebscher; Amit Roy; Xiaoning Wang; Ingo Roeder
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

Review 8.  Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR.

Authors:  Aleksandar Jovanovski; Jessica Petiti; Emilia Giugliano; Enrico Marco Gottardi; Giuseppe Saglio; Daniela Cilloni; Carmen Fava
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.